Baker Bros. Advisors’s Foghorn Therapeutics FHTX Stock Holding History

Baker Bros. Advisors’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-45,027	Closed	-$213K	–	92
2024 Q4	$213K	Hold	45,027	–	–	﹤0.01%	93
2024 Q3	$419K	Hold	45,027	–	–	﹤0.01%	90
2024 Q2	$259K	Hold	45,027	–	–	﹤0.01%	93
2024 Q1	$302K	Hold	45,027	–	–	﹤0.01%	83
2023 Q4	$290K	Hold	45,027	–	–	﹤0.01%	81
2023 Q3	$225K	Hold	45,027	–	–	﹤0.01%	100
2023 Q2	$317K	Hold	45,027	–	–	﹤0.01%	105
2023 Q1	$279K	Hold	45,027	–	–	﹤0.01%	102
2022 Q4	$287K	Hold	45,027	–	–	﹤0.01%	107
2022 Q3	$386K	Hold	45,027	–	–	﹤0.01%	109
2022 Q2	$612K	Hold	45,027	–	–	﹤0.01%	106
2022 Q1	$686K	Hold	45,027	–	–	﹤0.01%	113
2021 Q4	$1.03M	Buy	+45,027	New	+$647K	0.01%	116

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baker Bros. Advisors's FHTX Position: Q1 2025 in Review

Baker Bros. Advisors sold out of Foghorn Therapeutics (FHTX) in Q1 2025, closing a stake of 45,027 shares — an estimated $213K sold.

Baker Bros. Advisors first reported a position in FHTX in Q4 2021 and held it in 13 quarters. The position peaked at $1.03M in Q4 2021. 90 funds tracked by Wall St. Rank hold FHTX as of Q1 2025.

Baker Bros. Advisors reported no remaining Foghorn Therapeutics position as of Q1 2025 after selling out during the quarter.
Baker Bros. Advisors sold 45,027 Foghorn Therapeutics shares in Q1 2025, an estimated $213K.
Baker Bros. Advisors first reported a position in Foghorn Therapeutics in Q4 2021 and held it in 13 quarters.
Baker Bros. Advisors's Foghorn Therapeutics position peaked at $1.03M in Q4 2021.
90 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2025.

Based on Baker Bros. Advisors's 13F filing for Q1 2025, filed 15 May 2025.